GILD Stock Recent News
GILD LATEST HEADLINES
Gilead Sciences GILD announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday.
GILD tops Q2 earnings, raises 2025 guidance as HIV drugs Biktarvy and Descovy drive revenue growth.
A flurry of company earnings led to big stock moves early Friday.
Gilead Sciences, Inc. (NASDAQ:GILD ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Andrew D. Dickinson - Chief Financial Officer Daniel P.
While the top- and bottom-line numbers for Gilead (GILD) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Gilead Sciences, Inc.'s HIV franchise, led by Biktarvy, ensures stable cash flows through 2033, providing long-term visibility and a strong competitive advantage. The launch of Yeztugo, a biannual PrEP injection, could significantly expand Gilead's market share and drive future revenue growth. Valuation remains attractive: GILD trades below peer multiples, boasts robust margins, and offers a sector-leading dividend yield above 2.8%.
Gilead Sciences (GILD) came out with quarterly earnings of $2.01 per share, beating the Zacks Consensus Estimate of $1.95 per share. This compares to earnings of $2.01 per share a year ago.
Gilead Sciences on Thursday reported flat quarterly earnings on slightly higher revenue and raised its full-year financial outlook due largely to better-than-expected sales of HIV drugs.
Gilead Sciences, Inc. GILD will release earnings results for the second quarter, after the closing bell on Thursday, Aug. 7.
Let's look at five pharma and biotech companies, PFE, LLY, AMGN, GILD and NVO, which are scheduled to release their second-quarter 2025 results this week.